BACKGROUND: BRAF mutations in colorectal cancer (CRC) are disproportionately observed in tumors exhibiting microsatellite instability (MSI) and are associated with other prognostic factors. The independent association between BRAF mutation status and CRC survival, however, remains unclear. METHODS: We evaluated the association between the BRAF c.1799T>A (p.V600E) mutation and survival in individuals with incident invasive CRC diagnosed between 1997 and 2007 in Western Washington State. Tumor specimens were tested for this BRAF mutation and MSI status. We used Cox regression to estimate HRs and 95% confidence intervals (CI) for the association between BRAF mutation status and disease-specific and overall survival. Stratified analyses were conducted by age, sex, tumor site, stage, and MSI status. RESULTS: Among 1,980 cases tested, 12% were BRAF c.1799T>A (p.V600E) mutation-positive (n = 247). BRAF-mutated CRC was associated with poorer disease-specific survival adjusting for age, sex, time from diagnosis to enrollment, stage, and MSI status (HR, 1.43; 95% CI, 1.05-1.95). This association was limited to cases diagnosed at ages <50 (HR, 3.06; 95% CI, 1.70-5.52) and was not evident in cases with MSI-high tumors (HR, 0.94; 95% CI, 0.44-2.03). Associations with overall survival were similar. CONCLUSIONS: Our results show that the prevalence of BRAF mutations in CRC differs by patient and tumor characteristics and suggest that the association between BRAF status and CRC survival may differ by some of these factors. IMPACT: The presence of a BRAF c.1799T>A (p.V600E) mutation is associated with significantly poorer prognosis after CRC diagnosis among subgroups of patients. 2012 AACR
BACKGROUND:BRAF mutations in colorectal cancer (CRC) are disproportionately observed in tumors exhibiting microsatellite instability (MSI) and are associated with other prognostic factors. The independent association between BRAF mutation status and CRC survival, however, remains unclear. METHODS: We evaluated the association between the BRAF c.1799T>A (p.V600E) mutation and survival in individuals with incident invasive CRC diagnosed between 1997 and 2007 in Western Washington State. Tumor specimens were tested for this BRAF mutation and MSI status. We used Cox regression to estimate HRs and 95% confidence intervals (CI) for the association between BRAF mutation status and disease-specific and overall survival. Stratified analyses were conducted by age, sex, tumor site, stage, and MSI status. RESULTS: Among 1,980 cases tested, 12% were BRAF c.1799T>A (p.V600E) mutation-positive (n = 247). BRAF-mutated CRC was associated with poorer disease-specific survival adjusting for age, sex, time from diagnosis to enrollment, stage, and MSI status (HR, 1.43; 95% CI, 1.05-1.95). This association was limited to cases diagnosed at ages <50 (HR, 3.06; 95% CI, 1.70-5.52) and was not evident in cases with MSI-high tumors (HR, 0.94; 95% CI, 0.44-2.03). Associations with overall survival were similar. CONCLUSIONS: Our results show that the prevalence of BRAF mutations in CRC differs by patient and tumor characteristics and suggest that the association between BRAF status and CRC survival may differ by some of these factors. IMPACT: The presence of a BRAF c.1799T>A (p.V600E) mutation is associated with significantly poorer prognosis after CRC diagnosis among subgroups of patients. 2012 AACR
Authors: Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: Reetesh K Pai; Priya Jayachandran; Albert C Koong; Daniel T Chang; Shirley Kwok; Lisa Ma; Daniel A Arber; Raymond R Balise; Raymond R Tubbs; Bonnie Shadrach; Rish K Pai Journal: Am J Surg Pathol Date: 2012-05 Impact factor: 6.394
Authors: Laura A E Hughes; Elizabeth J Williamson; Manon van Engeland; Mark A Jenkins; Graham G Giles; John L Hopper; Melissa C Southey; Joanne P Young; Daniel D Buchanan; Michael D Walsh; Piet A van den Brandt; R Alexandra Goldbohm; Matty P Weijenberg; Dallas R English Journal: Int J Epidemiol Date: 2012-04-24 Impact factor: 7.196
Authors: Mai Yamauchi; Teppei Morikawa; Aya Kuchiba; Yu Imamura; Zhi Rong Qian; Reiko Nishihara; Xiaoyun Liao; Levi Waldron; Yujin Hoshida; Curtis Huttenhower; Andrew T Chan; Edward Giovannucci; Charles Fuchs; Shuji Ogino Journal: Gut Date: 2012-03-17 Impact factor: 23.059
Authors: Noralane M Lindor; Lawrence J Burgart; Olga Leontovich; Richard M Goldberg; Julie M Cunningham; Daniel J Sargent; Catherine Walsh-Vockley; Gloria M Petersen; Michael D Walsh; Barbara A Leggett; Joanne P Young; Melissa A Barker; Jeremy R Jass; John Hopper; Steve Gallinger; Bharati Bapat; Mark Redston; Stephen N Thibodeau Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: Ben Tran; Scott Kopetz; Jeanne Tie; Peter Gibbs; Zhi-Qin Jiang; Christopher H Lieu; Atin Agarwal; Dipen M Maru; Oliver Sieber; Jayesh Desai Journal: Cancer Date: 2011-03-31 Impact factor: 6.860
Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2002-06-09 Impact factor: 49.962
Authors: Mai Yamauchi; Paul Lochhead; Teppei Morikawa; Curtis Huttenhower; Andrew T Chan; Edward Giovannucci; Charles Fuchs; Shuji Ogino Journal: Gut Date: 2012-04-05 Impact factor: 23.059
Authors: NaNa Keum; Li Liu; Tsuyoshi Hamada; Zhi Rong Qian; Jonathan A Nowak; Yin Cao; Annacarolina da Silva; Keisuke Kosumi; Mingyang Song; Daniel Nevo; Molin Wang; Andrew T Chan; Jeffrey A Meyerhardt; Charles S Fuchs; Kana Wu; Shuji Ogino; Reiko Nishihara; Xuehong Zhang Journal: Cancer Causes Control Date: 2019-04-08 Impact factor: 2.506
Authors: Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope Journal: Clin Cancer Res Date: 2014-03-31 Impact factor: 12.531
Authors: Van Morris; Michael J Overman; Zhi-Qin Jiang; Christopher Garrett; Shweta Agarwal; Cathy Eng; Bryan Kee; David Fogelman; Arvind Dasari; Robert Wolff; Dipen Maru; Scott Kopetz Journal: Clin Colorectal Cancer Date: 2014-06-23 Impact factor: 4.481
Authors: Oscar Murcia; Miriam Juárez; Eva Hernández-Illán; Cecilia Egoavil; Mar Giner-Calabuig; María Rodríguez-Soler; Rodrigo Jover Journal: World J Gastroenterol Date: 2016-04-07 Impact factor: 5.742
Authors: A Joan Levine; Amanda I Phipps; John A Baron; Daniel D Buchanan; Dennis J Ahnen; Stacey A Cohen; Noralane M Lindor; Polly A Newcomb; Christophe Rosty; Robert W Haile; Peter W Laird; Daniel J Weisenberger Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-10-28 Impact factor: 4.254
Authors: Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino Journal: Am J Gastroenterol Date: 2014-06-17 Impact factor: 10.864